Physician profile
Shane E Thoreson
NPI 1508185828
$1,790.54
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $96.38 · 2021: $400 · 2022: $354 · 2023: $266 · 2024: $210 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.37 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $190.35 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $185.40 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $164.77 | 2020-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $163.34 | 2019-2022 | |
| Novo Nordisk INC | $158.86 | 2019-2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.44 | 2025 | Caplyta |
| Astellas Pharma US INC | $91.26 | 2019-2020 | |
| Pfizer INC. | $85.58 | 2023-2025 | |
| Mylan Specialty L.P. | $73.50 | 2019-2023 | Yupelri |
| Aimmune Therapeutics, INC. | $47.94 | 2025 | Zenpep |
| Sanofi-Aventis U.S. LLC | $38.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.52 | 2024-2025 | |
| Abbott Laboratories | $22.28 | 2021 | |
| Sumitomo Pharma America, INC. | $17.21 | 2025 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $15.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2024 | Trintellix |
| Viatris Specialty LLC | $14.46 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2023 | Livalo |
| Amarin Pharma, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Thoreson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.